Biotech’s Surge and the Investor’s Exit

The transaction, detailed in the SEC filing, reflects a strategic adjustment. Stonepine’s exposure to Indivior now constitutes 1.96% of its reportable assets under management, down from 5.06% in the prior quarter. This shift aligns with broader portfolio reallocations, as the fund maintains significant positions in other biotech firms.





